ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 662,30
-0,58%
Dow Jones
39 112,16
-0,76%
DAX
18 177,62
-0,90%
Brent Oil
84,595
0,49%
Bitcoin
61 872,51
0,11%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. SELLAS Life Sciences Group Inc (SLS)

  7. SELLAS Life Sciences Group Inc (SLS) Actualités

SLS

SELLAS Life Sciences (SLS)

SELLAS Life Sciences Group Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SLS
DateHeureSourceTitreSymboleSociété
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLSSELLAS Life Sciences Group Inc
14/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLSSELLAS Life Sciences Group Inc
25/01/202412h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLSSELLAS Life Sciences Group Inc
19/01/202422h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLSSELLAS Life Sciences Group Inc
05/01/202422h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLSSELLAS Life Sciences Group Inc
21/06/202312h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLSSELLAS Life Sciences Group Inc
28/04/202322h23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SLSSELLAS Life Sciences Group Inc
28/04/202322h14Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SLSSELLAS Life Sciences Group Inc
16/03/202321h08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SLSSELLAS Life Sciences Group Inc
24/02/202323h13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SLSSELLAS Life Sciences Group Inc
03/02/202323h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLSSELLAS Life Sciences Group Inc
15/11/202219h05TipRanksSELLAS Life Sciences Group (SLS) Gets a Buy from Maxim GroupNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202217h21TipRanksSELLAS Craters After Postponing Cancer Drug MilestoneNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202214h15GlobeNewswire Inc.SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial ResultsNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202213h50GlobeNewswire Inc.SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid LeukemiaNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202213h49Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SLSSELLAS Life Sciences Group Inc
11/11/202218h55TipRanksMaxim Group Reaffirms Their Buy Rating on SELLAS Life Sciences Group (SLS)NASDAQ:SLSSELLAS Life Sciences Group Inc
10/11/202214h30GlobeNewswire Inc.SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant AdvanceNASDAQ:SLSSELLAS Life Sciences Group Inc
03/11/202214h36GlobeNewswire Inc.SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual MeetingNASDAQ:SLSSELLAS Life Sciences Group Inc
02/11/202213h30GlobeNewswire Inc.SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022NASDAQ:SLSSELLAS Life Sciences Group Inc
17/10/202214h30GlobeNewswire Inc.SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022NASDAQ:SLSSELLAS Life Sciences Group Inc
11/10/202214h30GlobeNewswire Inc.SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-SNASDAQ:SLSSELLAS Life Sciences Group Inc
29/09/202214h15GlobeNewswire Inc.SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 FormulationsNASDAQ:SLSSELLAS Life Sciences Group Inc
22/09/202214h30GlobeNewswire Inc.SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual MeetingNASDAQ:SLSSELLAS Life Sciences Group Inc
14/09/202214h30GlobeNewswire Inc.SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28thNASDAQ:SLSSELLAS Life Sciences Group Inc
08/09/202214h00GlobeNewswire Inc.SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022NASDAQ:SLSSELLAS Life Sciences Group Inc
24/08/202214h30GlobeNewswire Inc.SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell LineNASDAQ:SLSSELLAS Life Sciences Group Inc
16/08/202222h08Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SLSSELLAS Life Sciences Group Inc
16/08/202214h30GlobeNewswire Inc.SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of DirectorsNASDAQ:SLSSELLAS Life Sciences Group Inc
11/08/202222h12GlobeNewswire Inc.SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:SLSSELLAS Life Sciences Group Inc
 Showing the most relevant articles for your search:NASDAQ:SLS

Dernières Valeurs Consultées

DGFX
NUMUSDT
NUM Token
USOTC
CAJPY
Canon (PK)
NYSE
NRC.CL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés